HARVARD BIOSCIENCE INC 8-K

What Happened Harvard Bioscience, Inc. announced preliminary financial results in a press release dated February 10, 2026, including unaudited revenue for the quarter ended December 31, 2025. The company filed an 8-K (Item 2.02) to disclose these preliminary figures and attached the press release as Exhibit 99.1.

Key Details

• The press release was issued on February 10, 2026 and covers preliminary results for the quarter ended December 31, 2025.
• The revenue figures disclosed are described as preliminary and unaudited.
• The preliminary estimates are not a comprehensive statement of fourth-quarter results and have not been audited, reviewed, or compiled by the company’s independent registered public accounting firm.
• The company warned that actual results may change after year‑end closing and auditing procedures are completed.

Why It Matters Preliminary, unaudited quarterly revenue gives investors an early look at recent performance but is subject to change. Retail investors should treat these figures as provisional and wait for the company’s finalized, audited results (and any related filings) before making decisions based on the quarter’s performance.